Detecting a potential safety signal of antidepressants and type 2 diabetes: a pharmacovigilance‐pharmacodynamic study

Siafis, Spyridon; Papazisis, Georgios

doi:10.1111/bcp.13699

Cited by 33 publications

(14 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study in female cynomolgus monkeys found that sertraline treatment was associated with decreased adiponectin levels, which could in turn promote insulin resistance . In humans, a study reported that adults using sertraline had about 50% greater risk of developing diabetes than those not using the medication, which was higher than for other antidepressants assessed in our study . As an SNRI, venlafaxine affects norepinephrine in addition to serotonin.…”

Section: Discussionsupporting

confidence: 85%

Antidepressant continuation in pregnancy and risk of gestational diabetes

Wartko

Weiss

Enquobahrie

et al. 2019

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

Purpose Previous studies observed modestly higher risk of gestational diabetes (GDM) associated with antidepressant use in pregnancy, potentially due to confounding by indication. We assessed the association of antidepressant continuation in pregnancy with GDM, as well as blood glucose levels, after accounting for confounding. Methods We conducted a retrospective cohort study of singleton live births from 2001 to 2014 to women enrolled in Kaiser Permanente Washington, an integrated health care delivery system, utilizing electronic health data and linked Washington State birth records. We required that women have ≥1 antidepressant prescription fills ≤6 months before pregnancy. Women with an antidepressant fill during pregnancy were categorized as “continuers” (n = 1634); those without a fill were “discontinuers” (n = 1211). We calculated relative risks (RRs) for GDM and mean differences in screening blood glucose levels using generalized estimating equations with inverse probability of treatment weighting to account for baseline characteristics, including mental health conditions and indicators of mental health severity. Results Compared with discontinuers, antidepressant continuers had comparable risk of GDM (RR: 1.10; 95% confidence interval [CI], 0.84‐1.44) and blood glucose levels (mean difference: 2.3 mg/dL; 95% CI, −1.5 to 6.1 mg/dL). We observed generally similar results for specific antidepressants, with the potential exceptions of risk of GDM associated with sertraline (RR: 1.30; 95% CI, 0.90‐1.88) and venlafaxine (RR: 1.52; 95% CI, 0.87‐2.68), but neither association was statistically significant. Conclusions Our study suggests that overall, women who continue antidepressants in pregnancy are not at increased risk for GDM or higher blood glucose, although further study may be warranted for sertraline and venlafaxine.

show abstract

Section: Discussionsupporting

confidence: 85%

Antidepressant continuation in pregnancy and risk of gestational diabetes

Wartko

Weiss

Enquobahrie

et al. 2019

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

“…FAERS is updated quarterly by the FDA, and it is one of the most extensive public databases in the world. To mine the FAERS, we used OpenVigil FDA, a validated pharmacovigilance tool, to retrieve FAERS data through the openFDA application programming interface for evaluating the FDA drug-event database with the additional openFDA duplicate detection and drug mapping functionality [ 10 , 11 ], and it is used in many pharmacovigilance studies [ 12 , 13 ]. OpenVigil operates only on the cleaned FDA data by deleting duplicates or reports with missing data [ 11 ].…”

Section: Methodsmentioning

confidence: 99%

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system

Huang

Jia²,

Sun

et al. 2020

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

Background To describe and analyze the patterns of adverse events associated with dipeptidyl peptidase-4 inhibitors (DPP-4is) (sitagliptin, saxagliptin, linagliptin, vildagliptin, and alogliptin) from the FDA Adverse Event Reporting System (FAERS) and to highlight areas of safety concerns. Methods Adverse events spontaneously submitted to the FAERS between 2004 Q1 to 2019 Q2 were included. The online tool OpenVigil 2.1 was used to query the database. The research relied on definitions of preferred terms (PTs) specified by the Medical Dictionary for Regulatory Activities (MedDRA) and the standardized MedDRA Queries (SMQ). The reporting odds ratio (ROR), with 95% confidence intervals (CIs) was calculated for disproportionality analysis. Results Over 16 years, a total of 9706 adverse event reports were identified. Alogliptin was excluded from further analysis due to insufficient sample size. Compared with the non-insulin antidiabetic drugs, the four DPP-4is were all disproportionately associated with four SMQs: “gastrointestinal nonspecific inflammation and dysfunctional conditions,” “hypersensitivity,” “severe cutaneous adverse reactions,” and “noninfectious diarrhoea”. As for PT level analyses, DPP-4is are associated with higher reporting of the gastrointestinal tract, pancreas, malignancies, infection, musculoskeletal disorders, general disorders, hypersensitivity, and skin AEs. Conclusions Data mining of the FAERS is useful for examining DPP-4 inhibitors-associated adverse events. The findings of the present study are compatible with clinical experience, and it provides valuable information to decision-makers and healthcare providers in clinical practice.

show abstract

“…The open-access nature of GtoPdb, along with is expert-backed curation, makes it an ideal resource for easily accessing quantitative binding data to help answer research questions. For example, in 2018 Siafis and Papzisis addressed the important question of why some antidepressants have been associated with development of diabetes ( 16 ). They used GtoPdb and the PDSP (Psychoactive Drug Screening Program) Ki database ( 17 ) to retrieve quantitative pharmacodynamic data for a set of 22 FDA-approved antidepressants.…”

Section: Guide To Pharmacology Updatesmentioning

confidence: 99%

The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials

Harding

Armstrong

Faccenda

et al. 2021

Nucleic Acids Research

132

110

View full text Add to dashboard Cite

The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb; www.guidetopharmacology.org) is an open-access, expert-curated database of molecular interactions between ligands and their targets. We describe expansion in content over nine database releases made during the last two years, which has focussed on three main areas of infection. The COVID-19 pandemic continues to have a major impact on health worldwide. GtoPdb has sought to support the wider research community to understand the pharmacology of emerging drug targets for SARS-CoV-2 as well as potential targets in the host to block viral entry and reduce the adverse effects of infection in patients with COVID-19. We describe how the database rapidly evolved to include a new family of Coronavirus proteins. Malaria remains a global threat to half the population of the world. Our database content continues to be enhanced through our collaboration with Medicines for Malaria Venture (MMV) on the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY (www.guidetomalariapharmacology.org). Antibiotic resistance is also a growing threat to global health. In response, we have extended our coverage of antibacterials in partnership with AntibioticDB.

show abstract

Detecting a potential safety signal of antidepressants and type 2 diabetes: a pharmacovigilance‐pharmacodynamic study

Cited by 33 publications

References 40 publications

Antidepressant continuation in pregnancy and risk of gestational diabetes

Antidepressant continuation in pregnancy and risk of gestational diabetes

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system

The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials

Contact Info

Product

Resources

About